ArticleJournal of global health2026
Clinical manifestations of Mycobacterium abscessus lung disease according to different morphotypes.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mycobacterium abscessus complex (MABC) displays phenotypic heterogeneity, primarily characterised by two distinct morphotypes: smooth and rough. However, the clinical manifestations, radiographic findings, and treatment outcomes of the two MABC morphotypes remain insufficiently characterised and poorly understood. We aimed to investigate the association between these morphotypes and clinical manifestations in a Taiwanese MABC-lung disease cohort. Methods: We conducted this study at a single centre in northern Taiwan. We enrolled patients diagnosed with MABC-lung disease (LD) and analysed their clinical characteristics in relation to MABC morphotypes. We also evaluated radiographic findings. Results: Among 121 patients with MABC-LD, the MABC isolates of 80 (66.1%) patients were smooth variants, and the remaining 41 (33.9%) were rough variants. Fewer patients with the rough variant of MABC had COPD and were smokers compared to patients with the smooth variant, but there were more patients with the rough variant (22.0%) compared to those with the smooth variant (5.0%) showing a fibrocavitary (FC) pattern on chest imaging (P = 0.017). Multivariable logistic regression analysis identified the rough morphotype as an independent factor associated with the FC pattern (adjusted odds ratio (aOR) = 4.741; 95% CI = 1.403-18.870, P = 0.016). Conversely, the FC pattern was the only significant correlated factor of rough morphotype (OR = 4.196; 95% CI = 1.183-17.771, P = 0.033). Conclusions: MABC-LD patients with rough-variant isolates had a higher rate of FC pattern compared with those with smooth-variant isolates. Given that an FC pattern may indicate poor prognosis, morphotypes of clinical isolates in MABC-LD may serve as a potential marker to guide clinical management, although further validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.